Elevation Oncology, Inc. Profile Avatar - Palmy Investing

Elevation Oncology, Inc.

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-…

Biotechnology
US, New York [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Elevation Oncology, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ELEV's Analysis
CIK: 1783032 CUSIP: 28623U101 ISIN: US28623U1016 LEI: - UEI: -
Secondary Listings
ELEV has no secondary listings inside our databases.